ERIS LIFESCIENCES LIMITED Q2 FY26 PAT stood at INR 134 Cr, up 39% YoY, with 17.0% PAT margin
AHMEDABAD, 13TH November: Eris Lifesciences Limited a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and half year ended September 30, 2025.
Q2 and H1 FY2026 Financial Performance Summary (Consolidated):
| Particulars (INR Cr) | Q2 FY26 | Q2 FY25 | YoY (%) | H1 FY26 | H1 FY25 | YoY (%) |
| Revenue from Operations | 792 | 741 | 6.9% | 1,565 | 1,461 | 7.2% |
| Gross Profit | 590 | 555 | 6.3% | 1,178 | 1,094 | 7.7% |
| EBITDA | 288 | 265 | 8.8% | 565 | 515 | 9.8% |
| EBITDA Margin (%) | 36.4% | 35.7% | 65 bps | 36.1% | 35.2% | 87 bps |
| Profit After Tax (PAT) | 134 | 97 | 38.7% | 260 | 186 | 39.6% |
| PAT Margin (%) | 17.0% | 13.1% | 389 bps | 16.6% | 12.7% | 385 bps |
Q2 and H1 FY2026 Key Financial Highlights:
- The DBF business reported revenue growth of 10% YoY in Q2 FY26 and 11% YoY in H1 FY26.
- Consolidated Revenue grew 7% YoY during both Q2 and H1 FY26 to Rs. 792 Cr and Rs. 1,565 Cr respectively.
- Consol EBITDA was Rs. 288 Cr in Q2, margin of 36.4% and Rs. 565 Cr with a margin of 36.1% during H1 FY26.
- PAT was Rs. 134 Cr in Q2 FY26, a PAT margin of 17.0%. For H1 FY26, PAT was Rs. 260 Cr, with a 16.6% margin.
- Net debt as of September 30, 2025, stood at Rs. 2,278 Cr.
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)
